Prevalence of antimicrobial resistant Escherichia coli from patients with suspected urinary tract infection in primary care, Denmark

Gloria Córdoba, Anne Holm, Frank Hansen, Anette M Hammerum, Lars Bjerrum, Gloria Córdoba, Anne Holm, Frank Hansen, Anette M Hammerum, Lars Bjerrum

Abstract

Background: Escherichia coli is the most common pathogen causing Urinary Tract Infections (UTI). Data from the current National Surveillance program in Denmark (DANMAP) may not accurately represent the prevalence of resistant E. coli in primary care, because only urine samples from complicated cases may be forwarded to the microbiological departments at hospitals for diagnostic examination. The aim of this study was to assess the prevalence of resistant E. coli to the most commonly used antimicrobial agents in primary care in a consecutive sample of patients from general practice.

Methods: Observational study carried out from December 2014 to December 2015. Thirty-nine general practices from The Capital Region of Denmark included adult patients with urinary tract symptoms and suspected UTI. All urine samples were sent to the central laboratory Statens Serum Institut (SSI). Significant bacteriuria was interpreted according to the European Urinalysis Standards. Susceptibility testing was performed and interpreted according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) standards.

Results: From the 39 general practices 505 patients were recruited. Completed data were obtained from 485 (96%) patients. According to the European Urinalysis Standards, 261 (54%) patients had positive bacteriuria. The most common uropathogen in patients with uncomplicated (uUTI) and complicated (cUTI) urinary tract infection was E. coli 105 (69%) and 76 (70%), respectively. Eighty-two (45%) of 181 E. coli isolates were resistant to at least one of the tested antibiotics and 50 out of 82 isolates were resistant to two or more antimicrobial agents. The highest resistance-rate was found against ampicillin 34% (95% CI 24;42) in uUTI and 36% (24;46) in cUTI. There were no differences in the distribution of resistance between uncomplicated and complicated cases. The prevalence of resistance was similar to the one reported in DANMAP 2014.

Conclusion: In E. coli from uUTI there is high resistance rates to antimicrobial agents commonly used in primary care. There was no difference in the distribution of resistant E. coli in suspected uUTI vs cUTI. In Denmark, data from the National Surveillance program DANMAP can guide the decision for choice of antibiotic in patients with suspected UTI seeking care in primary care.

Trial registration: ClinicalTrials.gov NCT02249273 .

Keywords: Antibiotic resistance; E. coli; Urinary tract infections.

Conflict of interest statement

Ethics approval and consent to participate

The study was approved by The Danish National Committee on Health Research ethics – Capital region (case number: H-4-2014-097). Informed written consent was obtained from all patients participating in the study.

Consent for publication

not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Flow chart of the study population
Fig. 2
Fig. 2
Distribution of susceptible and resistant E. coli isolates in uncomplicated and complicated cases

References

    1. World Economic Forum. Global Risks 2013. Geneva. 2013. . Accessed 8 June 2017.
    1. Statens Serum Institut. DANMAP 2014-use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, food and humans in Denmark. 2014. . Accessed 8 June 2017.
    1. Swedres– Svarm 2014.Consumption of antibiotics and occurrence of antibiotic resistance in Sweden. 2014. . Accessed 8 June 2017.
    1. O’Brien K, Bellis TW, Kelson M, Hood K, Butler CC, Edwards A. Clinical predictors of antibiotic prescribing for acutely ill children in primary care: an observational study. Br J Gen Pract. 2015;65:e585–e592. doi: 10.3399/bjgp15X686497.
    1. Pace WD, Dickinson LM, Staton EW. Seasonal variation in diagnoses and visits to family physicians. Ann Fam Med. 2004;2:411–417. doi: 10.1370/afm.73.
    1. Etienne M, Lefebvre E, Frebourg N, Hamel H, Pestel-Caron M, Caron F. Antibiotic treatment of acute uncomplicated cystitis based on rapid urine test and local epidemiology: lessons from a primary care series. BMC Infect Dis. 2014;14:1–8. doi: 10.1186/1471-2334-14-137.
    1. Schito GC, Naber KG, Botto H, Palou J, Mazzei T, Gualco L, et al. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob Agents. 2009;34:407–413. doi: 10.1016/j.ijantimicag.2009.04.012.
    1. Allocati N, Masulli M, Alexeyev MF, Di Ilio C. Escherichia coli in Europe: an overview. Int J environ res. Public Health. 2013;10(12):6235–54.
    1. The European Antimicrobial Resistance Surveillance Network (EARS-Net). . Accessed 8 June 2017.
    1. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52:e103–e120. doi: 10.1093/cid/ciq257.
    1. Scotish Intercollegiate Guidelines Network. Management of suspected bacterial urinary tract infection in adults: a national clinical guideline. 2015. . Accessed 8 June 2017.
    1. Hillier S, Bell J, Heginbothom M, Roberts Z, Dunstan F, Howard A, et al. When do general practitioners request urine specimens for microbiology analysis? The applicability of antibiotic resistance surveillance based on routinely collected data. J Antimicrob Chemother. 2006;58:1303–1306. doi: 10.1093/jac/dkl432.
    1. Kamenski G, Wagner G, Zehetmayer S, Fink W, Spiegel W, Hoffmann K. Antibacterial resistances in uncomplicated urinary tract infections in women: ECO·SENS II data from primary health care in Austria. BMC Infect Dis. 2012;12:1–8. doi: 10.1186/1471-2334-12-222.
    1. European Confederation of Laboratory Medicine. European urinanalysis guidelines. Scand J Clin Lab Invest Suppl. 2000;231:1–86.
    1. European Committee on Antimicrobial susceptibility testing. . Accessed 8 June 2017.
    1. Johansen TE, Botto H, Cek M, Grabe M, Tenke P, Wagenlehner FM, et al. Critical review of current definitions of urinary tract infections and proposal of an EAU/ESIU classification system. Int J Antimicrob Agents. 2011;38:64–70. doi: 10.1016/j.ijantimicag.2011.09.009.
    1. Schmiemann G, Gágyor I, Hummers-Pradier E, Bleidorn J. Resistance profiles of urinary tract infections in general practice - an observational study. BMC Urol. 2012;12:1–5. doi: 10.1186/1471-2490-12-33.
    1. Falagas ME, Polemis M, Alexiou VG, Marini-Mastrogiannaki A, Kremastinou J, Vatopoulos AC. Antimicrobial resistance of Esherichia coli urinary isolates from primary care patients in Greece. Med Sci Monit. 2008;14:Cr75–Cr79.
    1. Kahlmeter G, Poulsen HO. Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO.SENS study revisited. Int J Antimicrob Agents. 2012;39(1):45–51.
    1. Shaifali I, Gupta U, Mahmood SE, Ahmed J. Antibiotic susceptibility patterns of urinary pathogens in female outpatients. N Am J Med Sci. 2012;4:163–169. doi: 10.4103/1947-2714.94940.
    1. Pitout JD, Laupland KB. Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8:159–166. doi: 10.1016/S1473-3099(08)70041-0.
    1. Hertz FB, Nielsen JB, Schønning K, Littauer P, Knudsen JD, Løbner-Olesen A, et al. Population structure of drug-susceptible, −resistant and ESBL-producing Escherichia coli from community-acquired urinary tract infections. BMC Microbiol. 2016;16:1–6. doi: 10.1186/s12866-015-0617-z.
    1. Tian SF, Chen BY, Chu YZ, Wang S. Prevalence of rectal carriage of extended-spectrum β-lactamase-producing Escherichia coli among elderly people in community settings in China. Can J Microbiol. 2008;54:781–785. doi: 10.1139/W08-059.
    1. Vinue L, Saenz Y, Martinez S, Somalo S, Moreno MA, Torres C, et al. Prevalence and diversity of extended-spectrum beta-lactamases in faecal Escherichia coli isolates from healthy humans in Spain. Clin Microbiol Infect. 2009;15:954–957. doi: 10.1111/j.1469-0691.2009.02803.x.
    1. Prakash V, Lewis JS, Herrera ML, Wickes BL, Jorgensen JH. Oral and parenteral therapeutic options for outpatient urinary infections caused by Enterobacteriaceae producing CTX-M extended-Spectrum β-Lactamases. Antimicrob Agents Chemother. 2009;53:1278–1280. doi: 10.1128/AAC.01519-08.
    1. Institute for rational pharmacotherapy. Systemic antibiotics. 2016. . Accessed 8 June 2017.
    1. Arendrup K, Arpi M, Lindhardt B, Carlsen C, Unkerskov J, Møller N, Jakobsen H. Guidelines for antibiotic use in General practice - Capital region. 2016. . Accessed 8 June 2017.
    1. Region Sjælland. Guideline for use of antibiotics in General Practice - North Region. 2016. . Accessed 8 June 2017.
    1. Huttner A, Verhaegh EM, Harbarth S, Muller AE, Theuretzbacher U, Mouton JW. Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials. J Antimicrob Chemother. 2015;70:2456–2464. doi: 10.1093/jac/dkv147.
    1. Sastry S, Doi Y. Fosfomycin: resurgence of an old companion. J Infect Chemother. 2016;22(5):273–80.
    1. Falagas ME, Vouloumanou EK, Togias AG, Karadima M, Kapaskelis AM, Rafailidis PI, et al. Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2010;65:1862–1877. doi: 10.1093/jac/dkq237.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner